List of works - Michael Wang

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

scientific article

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

article

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

scientific article

Structure of N-Terminal Domain of NPC1 Reveals Distinct Subdomains for Binding and Transfer of Cholesterol

scientific article

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

scientific article

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

scientific article

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

scientific article

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

scientific article

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis

scientific article published on 26 August 2009

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

scientific article

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

scientific article published on June 11, 2014

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

scientific article

Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.

scientific article

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

scientific article published on July 30, 2012

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

scientific article published on 17 September 2008

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

scientific article

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

scientific article

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma

scientific article

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

scientific article

Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

scientific article published on 26 May 2010

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

scientific article

Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma

scientific article published on September 14, 2012

Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide

scientific article

Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells

scientific article published on September 11, 2012

Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis

scientific article

Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.

scientific article published on 17 April 2018

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

scientific article published on 16 February 2016

Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma

scientific article

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

scientific article

Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer

scientific article

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

scientific article

Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies

scientific article published on October 2006

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

scientific article published on 01 February 2020

Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.

scientific article

Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma

scientific article published on 21 September 2009

Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells

scientific article

Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo

scientific article published on November 2, 2010

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.

scientific article

Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma

scientific article published in December 2008

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma

scientific article

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.

scientific article

Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study.

scientific article published on 2 December 2011

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

scientific article published on 20 July 2016

Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

scientific article published on August 5, 2010

Osteoblastic niche supports the growth of quiescent multiple myeloma cells

scientific article

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

scientific article published on 27 July 2015

Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.

scientific article

Effect of long-term storage in TRIzol on microarray-based gene expression profiling

scientific article published on 30 August 2010

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma

scientific article published on 24 August 2011

Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma

scientific article published on 6 October 2006

List of works by Michael Wang

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Structure of N-Terminal Domain of NPC1 Reveals Distinct Subdomains for Binding and Transfer of Cholesterol

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma

Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide

Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells

Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis

Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.

Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma

Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells

Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.

Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.

Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study.

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

Osteoblastic niche supports the growth of quiescent multiple myeloma cells

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.

Effect of long-term storage in TRIzol on microarray-based gene expression profiling

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma

Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma